Sugi Predict

Sugi Predict / Compounds / SCHEMBL25319683

SCHEMBL25319683

SCHEMBL25319683

CC(C)(C)OC(=O)N[C@H]1CCC[C@@H](CO)C1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.64
▸ KMT2A Q03164 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ EPHX1 P07099 2/20 0.47
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ GAA P10253 1/20 0.44
▸ CTSK P43235 2/20 0.43
▸ DRD2 P14416 2/20 0.41
▸ KDM1A O60341 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ NR1H2 P55055 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ RELA Q04206 1/20 0.40
▸ CYP2C9 P11712 1/20 0.39
▸ HSD11B1 P28845 1/20 0.39
▸ KAT8 Q9H7Z6 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2377443 1.00 BTK (0.64) BTKKMT2AL3MBTL1EPHX1CA1
SCHEMBL941563 1.00 BTK (0.64) BTKKMT2AL3MBTL1EPHX1CA1
SCHEMBL15909157 1.00 BTK (0.64) BTKKMT2AL3MBTL1EPHX1CA1
SCHEMBL21027650 1.00 BTK (0.64) BTKKMT2AL3MBTL1EPHX1CA1
SCHEMBL941984 1.00 BTK (0.64) BTKKMT2AL3MBTL1EPHX1CA1
SCHEMBL25524123 1.00 BTK (0.64) BTKKMT2AL3MBTL1EPHX1CA1
SCHEMBL14084772 0.97 BTK (0.60) BTKKMT2AL3MBTL1EPHX1CA1
SCHEMBL3906349 0.91 BTK (0.55) BTKKMT2AL3MBTL1EPHX1CA1
SCHEMBL19156343 0.91 BTK (0.55) BTKKMT2AL3MBTL1EPHX1CA1
SCHEMBL3903151 0.91 BTK (0.55) BTKKMT2AL3MBTL1EPHX1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459922-B2 PARP7 inhibitors GILEAD SCIENCES, INC. (US) 2025-11-04 — — US disclosed
US-20250100998-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. 2025-03-27 — — US disclosed
WO-2025024811-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. (US) 2025-01-30 — — WO disclosed
EP-4469448-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. (US) 2024-12-04 — — EP disclosed
US-20230365529-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. 2023-11-16 — — US disclosed
US-20230365529-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. 2023-11-16 — — US disclosed
US-20230312557-A1 P2X3 MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2023-10-05 — — US disclosed
WO-2023147418-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. (US) 2023-08-03 — — WO disclosed
EP-4103564-A1 P2X3 MODULATORS Bellus Health Cough Inc. (CA) 2022-12-21 — — EP disclosed
CN-115413279-A P2X3 modulators 贝卢斯医疗咳嗽病公司 2022-11-29 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312557-A1 P2X3 MODULATORS P2RX3, P2RX2, P2RX6 BTK 3126/4885KMT2A 4284/4885L3MBTL1 4348/4885
US-20250100998-A1 PARP7 INHIBITORS PARP1, PARP11, PARP2 BTK 1242/4885KMT2A 821/4885L3MBTL1 3326/4885
US-12459922-B2 PARP7 inhibitors PARP1, PARP11, PARP2 BTK 1242/4885KMT2A 821/4885L3MBTL1 3326/4885
US-20230365529-A1 PARP7 INHIBITORS PARP1, PARP11, PARP2 BTK 1242/4885KMT2A 821/4885L3MBTL1 3326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.